Table 1.
Baseline characteristics for patients who received ceftaroline
| Variable | All (n=764) |
Skin (n=307) |
Sepsis (n=233) |
Osteo (n=193) |
Diab foot (n=170) |
Pneumonia (n=124) |
Bact (n=87) |
Endo (n=46) |
Mening (n=18) |
Device (n=15) |
|---|---|---|---|---|---|---|---|---|---|---|
| Age (years), median (IQR) | 61 (54–67) |
60 (54–66) |
61 (55–69) |
60 (54–66) |
61 (56–66) |
62 (56–70) |
60 (54–67) |
63 (58–73) |
61 (58–74) |
63 (54–71) |
| Male, % | 97% | 96% | 97% | 98% | 98% | 98% | 98% | 98% | 94% | 100% |
| Married, % | 41% | 39% | 40% | 43% | 39% | 44% | 33% | 48% | 22% | 33% |
| Charlson Score, median (IQR) | 6 (3–8) | 6 (3–7) | 6 (4–8) | 6 (4–8) | 6 (4–8) | 6 (3–9) | 6 (4–9) | 5(4–7) | 5 (3–8) | 8 (5–9) |
| Selected Comorbidities, % | ||||||||||
| Congestive heart failure | 25% | 26% | 29% | 22% | 26% | 28% | 30% | 43% | 22% | 40% |
| COPD | 33% | 32% | 34% | 27% | 32% | 53% | 29% | 33% | 22% | 27% |
| Cerebrovascular disease | 14% | 11% | 17% | 14% | 11% | 17% | 18% | 22% | 6% | 20% |
| Dementia | 1% | <1% | 2% | 1% | 0% | 2% | 5% | 4% | 0% | 7% |
| Diabetes (complications) | 32% | 35% | 31% | 46% | 59% | 19% | 36% | 13% | 39% | 47% |
| Diabetes (no complications) | 56% | 63% | 55% | 72% | 99% | 41% | 61% | 41% | 61% | 53% |
| Hemi/paraplegia | 4% | 1% | 5% | 4% | 1% | 6% | 7% | 4% | 17% | 13% |
| HIV | 1% | 2% | 1% | 1% | 1% | 2% | 3% | 2% | 0% | 0% |
| AIDS | 3% | 5% | 3% | 2% | 1% | 4% | 6% | 2% | 6% | 0% |
| Liver (mild) | 2% | 4% | 3% | 3% | 3% | 2% | 6% | 0% | 0% | 7% |
| Liver (mod/severe; cirrhosis) | 6% | 9% | 8% | 4% | 9% | 4% | 9% | 4% | 0% | 13% |
| Cancer | 19% | 13% | 21% | 17% | 14% | 26% | 17% | 20% | 22% | 33% |
| Leukemia | 3% | 3% | 6% | 2% | 1% | 7% | 2% | 2% | 0% | 0% |
| Metastatic cancer | 4% | 2% | 4% | 3% | 1% | 8% | 3% | 0% | 0% | 7% |
| Myocardial infarction | 9% | 7% | 12% | 9% | 8% | 10% | 14% | 17% | 17% | 27% |
| Peripheral vascular disease | 24% | 24% | 20% | 31% | 31% | 22% | 14% | 22% | 6% | 40% |
| Renal disease | 32% | 28% | 37% | 32% | 35% | 31% | 40% | 33% | 22% | 47% |
| Dyslipidemia | 65% | 64% | 61% | 63% | 78% | 60% | 51% | 70% | 33% | 80% |
| Hypertension | 81% | 80% | 81% | 87% | 92% | 76% | 84% | 80% | 83% | 93% |
| Hemodialysis | 2% | 0% | 4% | 2% | 0% | 2% | 6% | 4% | 0% | 20% |
| Hospitalization (past 90d), % | 40% | 36% | 41% | 47% | 37% | 41% | 49% | 43% | 44% | 53% |
| Antibiotics (past 90d), % | 87% | 88% | 90% | 89% | 88% | 88% | 91% | 83% | 78% | 93% |
| ICU, % | 19% | 8% | 30% | 12% | 6% | 37% | 21% | 26% | 22% | 27% |
| Weight (lb.), median (IQR) | 201 (167–245) |
215 (179–261) |
195 (164–242) |
202 (166–244) |
224 (187–277) |
179 (151–219) |
195 (166–234) |
179 (158–212) |
210 (184–237) |
202 (176–249) |
Osteo: osteomyelitis; Diab foot: diabetic foot infections; Bact: bacteremia; Endo: endocarditis; Mening: meningitis; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; ICU: intensive care unit